Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

SANJAY CHABRA

Allopathic & Osteopathic Physicians Internal Medicine Rheumatology

NPI
1316916125
CMS profile
241418
Location
EL PASO, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$586,206.39

842 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

By paying entity

PY2019 · entire year · sorted by reported total

Paying entityAmountRecords
Horizon Therapeutics plc $120,927.14 117
Celgene Corporation $116,415.85 117
Lilly USA, LLC $99,935.32 160
AbbVie, Inc. $72,509.39 105
Novartis Pharmaceuticals Corporation $42,886.20 60
GENZYME CORPORATION $32,075.21 37
Amgen Inc. $30,158.66 76
Mallinckrodt Enterprises LLC $23,959.54 35
UCB, Inc. $21,490.99 41
PFIZER INC. $15,708.21 32
GlaxoSmithKline, LLC. $4,920.57 16
Regeneron Healthcare Solutions, Inc. $3,551.35 13
SANOFI-AVENTIS U.S. LLC $774.20 17
Janssen Biotech, Inc. $664.14 5
Flexion Therapeutics, Inc. $82.91 3
E.R. Squibb & Sons, L.L.C. $41.26 2
Sobi, Inc $31.27 2
DePuy Synthes Sales Inc. $24.66 1
Takeda Pharmaceuticals U.S.A., Inc. $20.84 1
Daiichi Sankyo Inc. $16.92 1
Radius Health, Inc. $11.76 1

Page 13 of 17; records 601–650 of 842 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

SANJAY CHABRA

NPI 1316916125 · CMS profile ID 241418

Allopathic & Osteopathic Physicians / Internal Medicine / Rheumatology

EL PASO, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 13 of 17; records 601–650 of 842 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1316916125?year=2019&recipient=provider&page=13#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
SANJAY CHABRA, NPI 1316916125, CMS profile ID 241418. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 13 of 17; records 601–650 of 842 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1316916125?year=2019&recipient=provider&page=13#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). SANJAY CHABRA, NPI 1316916125, CMS profile ID 241418. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 13 of 17; records 601–650 of 842 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1316916125?year=2019&recipient=provider&page=13#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
SANJAY CHABRA, NPI 1316916125, CMS profile ID 241418, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 13 of 17; records 601–650 of 842 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1316916125?year=2019&recipient=provider&page=13#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

842 matching records · $586,206.39 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 842 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 601–650 of 842.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Celgene Corporation $86.4404/23/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672904047 CMS
Celgene Corporation $2,038.0004/23/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672907678 CMS
Celgene Corporation $544.0004/23/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673021501 CMS
Novartis Pharmaceuticals Corporation $2,525.0004/22/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658813731 CMS
Novartis Pharmaceuticals Corporation $24.1704/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658813735 CMS
Novartis Pharmaceuticals Corporation $22.7704/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659144522 CMS
Amgen Inc. $1,514.5004/18/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 663006673 CMS
Amgen Inc. $20.6804/17/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 663006624 CMS
Horizon Therapeutics plc $124.9904/15/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 691346455 CMS
Horizon Therapeutics plc $3,240.0004/15/2019 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 691346457 CMS
Horizon Therapeutics plc $20.6504/15/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 691346461 CMS
Amgen Inc. $27.8304/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 663006525 CMS
Horizon Therapeutics plc $28.6804/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 691346425 CMS
Horizon Therapeutics plc $113.4904/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 691346428 CMS
Horizon Therapeutics plc $5,400.0004/11/2019 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 691346431 CMS
Horizon Therapeutics plc $548.1504/11/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 691346435 CMS
Horizon Therapeutics plc $3,240.0004/11/2019 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 691346438 CMS
Horizon Therapeutics plc $129.2604/11/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 691346441 CMS
Horizon Therapeutics plc $65.9604/11/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 691346445 CMS
Horizon Therapeutics plc $387.6104/11/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 691346447 CMS
Horizon Therapeutics plc $43.7304/11/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 691346451 CMS
Regeneron Healthcare Solutions, Inc. $425.6004/11/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673358033 CMS
Regeneron Healthcare Solutions, Inc. $35.2504/11/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673358035 CMS
Lilly USA, LLC $13.6804/10/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658122987 CMS
Lilly USA, LLC $5.2504/10/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658122993 CMS
Lilly USA, LLC $216.0004/10/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658126303 CMS
Lilly USA, LLC $230.4004/10/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658126305 CMS
Lilly USA, LLC $1,575.0004/10/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658126315 CMS
Lilly USA, LLC $18.0004/10/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658126327 CMS
Lilly USA, LLC $75.0004/10/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658136591 CMS
Lilly USA, LLC $1,800.0004/10/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658143273 CMS
Lilly USA, LLC $687.6704/10/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658146227 CMS
AbbVie, Inc. $2,000.0004/09/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 648246903 CMS
AbbVie, Inc. $2,800.0004/09/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 648246909 CMS
Novartis Pharmaceuticals Corporation $21.9804/09/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659144483 CMS
Celgene Corporation $2,038.0004/08/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672903077 CMS
Celgene Corporation $14.0704/08/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672906927 CMS
Celgene Corporation $64.2604/08/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672912835 CMS
Celgene Corporation $2,552.7504/08/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672929927 CMS
Celgene Corporation $174.9704/08/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672931797 CMS
Celgene Corporation $4,518.0004/08/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672932119 CMS
Celgene Corporation $16.1704/08/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672936423 CMS
Lilly USA, LLC $442.2004/05/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658133081 CMS
Lilly USA, LLC $398.0404/05/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658133089 CMS
Lilly USA, LLC $1,575.0004/05/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658136583 CMS
Lilly USA, LLC $1,800.0004/05/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658139925 CMS
AbbVie, Inc. $24.3204/04/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 648246901 CMS
AbbVie, Inc. $24.3604/04/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 648246905 CMS
AbbVie, Inc. $134.5604/04/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 648246907 CMS
AbbVie, Inc. $796.8104/04/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 648246911 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $586,206.39 842
PY2020 $298,980.17 504
PY2021 $433,151.25 611
PY2022 $575,711.32 843
PY2023 $486,098.23 661
PY2024 $500,130.81 668
PY2025 $411,668.30 531

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $77,380.59 12
PY2024 Principal investigator $28,318.50 8
PY2023 Principal investigator $10,226.00 5
PY2022 Principal investigator $161,148.13 3
PY2021 Principal investigator $6,420.13 1
PY2019 Principal investigator $1,587.00 1

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

12 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Genentech, Inc. $698.00 11/24/2025 Non-covered Recipient Entity
TEXAS ARTHRITIS CENTER
Study to investigate safety and efficiacy of Obinutuzumab in Patients with SLE No dispute reported 06/30/2026 1211662768
Principal investigator 1 Genentech, Inc. $5,807.01 09/22/2025 Non-covered Recipient Entity
TEXAS ARTHRITIS CENTER
Randomised Double blind study to evaluate safety and efficacy of Obinutuzumab in Class III and IV LN No dispute reported 06/30/2026 1211662761
Principal investigator 1 AstraZeneca Pharmaceuticals LP $1,896.08 07/23/2025 Non-covered Recipient Entity
TEXAS ARTHRITIS CENTER, PA
Multicenter Randomized Double-Blind Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Anifrolumab in Adult Patients with Active Proliferative Lupus Nephritis No dispute reported 06/30/2026 1185542920
Principal investigator 1 Aurinia Pharma U.S., Inc. $2,500.00 07/16/2025 Non-covered Recipient Entity
Sanjay Chabra dba Texas Arthritis Center
LUPKYNIS Registry Study No dispute reported 06/30/2026 1243931250
Principal investigator 1 Genentech, Inc. $27,105.00 07/14/2025 Non-covered Recipient Entity
TEXAS ARTHRITIS CENTER
Study to investigate safety and efficiacy of Obinutuzumab in Patients with SLE No dispute reported 06/30/2026 1211662765
Principal investigator 1 Novartis Pharmaceuticals Corporation $5,822.04 07/09/2025 Non-covered Recipient Entity
TEXAS ARTHRITIS CENTER
A Randomized, Double-blind, Parallel Group, Placebo-controlled Multicenter Phase 3 Study to Evaluate Efficacy, Safety and Tolerability of Two Regimens of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SL No dispute reported 06/30/2026 1190309834
Principal investigator 1 Aurinia Pharma U.S., Inc. $845.00 05/07/2025 Non-covered Recipient Entity
Sanjay Chabra dba Texas Arthritis Center
LUPKYNIS Registry Study No dispute reported 06/30/2026 1243930745
Principal investigator 1 Aurinia Pharma U.S., Inc. $5,000.00 05/07/2025 Non-covered Recipient Entity
Sanjay Chabra dba Texas Arthritis Center
LUPKYNIS Registry Study No dispute reported 06/30/2026 1243930747
Principal investigator 1 AstraZeneca Pharmaceuticals LP $1,896.08 04/17/2025 Non-covered Recipient Entity
AGA CLINICAL TRIALS
Multicenter Randomized Double-Blind Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Anifrolumab in Adult Patients with Active Proliferative Lupus Nephritis No dispute reported 06/30/2026 1185542922
Principal investigator 1 Novartis Pharmaceuticals Corporation $22,312.16 03/31/2025 Non-covered Recipient Entity
TEXAS ARTHRITIS CENTER
An Open-label, Multicenter Study to Evaluate Pharmacokinetics, Safety and Tolerability up to 6 Years of Intravenous Secukinumab Infusions in Pediatric Participants With Juvenile Psoriatic Arthritis No dispute reported 06/30/2026 1190309832
Principal investigator 1 Aurinia Pharma U.S., Inc. $2,535.00 03/12/2025 Non-covered Recipient Entity
Sanjay Chabra dba Texas Arthritis Center
LUPKYNIS Registry Study No dispute reported 06/30/2026 1243930956
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $964.22 01/21/2025 Non-covered Recipient Entity
Texas Arthritis Center, Pa
A Study to Evaluate Effectiveness and Safety of Deucravacitinib (BMS-986165) Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (POETYK SLE-2) No dispute reported 06/30/2026 1235993335